Newsroom | 45474 results

Sorted by: Latest
Clinical Trials
-

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio announces preclinical data on its mitochondrial protonophore portfolio at the American Diabetes Association’s 85th Scientific Sessions....
-

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the Americ...
-

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis...
-

Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer

MADISON, Wis.--(BUSINESS WIRE)--Archeus Technologies, a company developing radiopharmaceutical therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer. This IND clearance enables Archeus to initiate a Phase 1 clinical trial in men with metas...
-

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneously in combination with Polivy® (polatuzumab vedotin-piiq) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to Rituxan®...
-

Northwell’s Sandra Lindsay to Be Inducted as a Fellow of the American Academy of Nursing

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Honoring her courage during the COVID-19 pandemic and her tireless advocacy for the medical and scientific community throughout her career, Northwell Health’s Sandra Lindsay, DHSc, MBA, RN, vice president of public health advocacy, has been named a Fellow of the American Academy of Nursing. The Academy is a policy organization and an honorific society that recognizes nursing’s most accomplished leaders in policy, research, practice, administration and acade...
-

Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation st...
-

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues....
-

Chiesi Global Rare Diseases assegna finanziamenti per la ricerca per promuovere l'innovazione nelle malattie lisosomiali

PARMA, Italia--(BUSINESS WIRE)--Chiesi Global Rare Diseases, una business unit del Gruppo Chiesi, creata per offrire soluzioni innovative alle persone affette da malattie rare, oggi ha annunciato i destinatari del suo programma di finanziamenti per la ricerca "Find For Rare". L'iniziativa di borse per la ricerca, guidata da esperti e valutata in modo indipendente, mira a migliorare la cura e la gestione dei pazienti riconoscendo la ricerca innovativa in tre malattie lisosomiali: la malattia di...
-

Chiesi Global Rare Diseases otorga becas de investigación para impulsar la innovación en el ámbito de las enfermedades lisosomales

PARMA, Italia--(BUSINESS WIRE)--Chiesi Global Rare Diseases, una unidad de negocio del Grupo Chiesi que se creó para brindar soluciones innovadoras a las personas que padecen enfermedades raras, anunció el día de hoy los beneficiarios de su programa de becas de investigación "Find For Rare". Esta iniciativa de becas de investigación, que fue evaluada de forma independiente y dirigida por expertos, tiene como objetivo mejorar la atención y el tratamiento de los pacientes mediante el reconocimien...